

PHARMACY POLICY STATEMENT

Indiana Medicaid

DRUG NAME	Wainua (eplontersen)
BENEFIT TYPE	Pharmacy
STATUS	Prior Authorization Required

Wainua is a ligand-conjugated antisense oligonucleotide (LICA) indicated for treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. It inhibits hepatic synthesis of human transthyretin (TTR) protein by causing degradation of mutant and wild-type TTR mRNA through binding to the TTR mRNA, which results in a reduction of serum TTR protein and TTR protein deposits in tissues. Efficacy was demonstrated in the NEURO-TTRansform clinical trial. hATTR is a rare and progressive inherited disorder where misfolded TTR accumulates as amyloid fibrils in the body. In polyneuropathy of hATTR (hATTR-PN), these fibrils deposit in the peripheral nerves which leads to pain, muscle weakness, and autonomic dysfunction. It is a monthly self-administered subcutaneous injection.

Wainua (eplontersen) will be considered for coverage when the following criteria are met:

Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis): Polyneuropathy

For **initial** authorization:

- 1.



CareSource considers